Urapidil hydrochloride

Cat. No.: HY-B0354A Purity: ≥99.0%: FAQs
Data Sheet SDS COA Handling Instructions

Urapidil hydrochloride is an orally active α1-adrenoceptor antagonist and 5-HT_1A receptor agonist with a pIC₅₀ of 6.13 and 4.38 against α1- and α2-adrenoceptor, respectively. Urapidil hydrochloride shows antihypertensive effect.

For research use only. We do not sell to patients.

Urapidil hydrochloride Chemical Structure

CAS No. : 64887-14-5

Size	Price	Stock	Quantity
Free Sample (0.1 - 0.5 mg)		Apply Now
50 mg	USD 50	In-stock	Estimated Time of Arrival: December 31
100 mg	USD 80	In-stock	Estimated Time of Arrival: December 31
200 mg		Get quote
500 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other Forms of Urapidil hydrochloride:

Urapidil In-stock

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All 5-HT Receptor Isoform Specific Products:

View All Isoforms

5-HT₁ Receptor 5-HT₂ Receptor 5-HT₃ Receptor 5-HT₄ Receptor 5-HT₅ Receptor 5-HT₆ Receptor 5-HT₇ Receptor 5-HT Receptor

View All Adrenergic Receptor Isoform Specific Products:

View All Isoforms

α adrenergic receptor β adrenergic receptor

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target

5-HT_1A Receptor

α adrenergic receptor

α1-adrenergic receptor

6.13 (pIC₅₀)

α2-adrenergic receptor

4.38 (pIC₅₀)

In Vivo

Urapidil (p.o. or i.v.) causes sedation and decreased tonus in mice and rats^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

Molecular Weight

423.94

Appearance

Solid

Formula

C₂₀H₃₀ClN₅O₃

CAS No.

64887-14-5

SMILES

O=C1N(C)C(C=C(NCCCN2CCN(C3=CC=CC=C3OC)CC2)N1C)=O.Cl

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility

In Vitro:

H₂O : 100 mg/mL (235.88 mM; Need ultrasonic)

DMSO : 14.29 mg/mL (33.71 mM; ultrasonic and warming and heat to 60°C)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.3588 mL	11.7941 mL	23.5882 mL
5 mM	0.4718 mL	2.3588 mL	4.7176 mL
10 mM	0.2359 mL	1.1794 mL	2.3588 mL

*Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: PBS
Solubility: 50 mg/mL (117.94 mM); Clear solution; Need ultrasonic
2.

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 1.25 mg/mL (2.95 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 1.25 mg/mL (2.95 mM); Clear solution
4.

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 1.25 mg/mL (2.95 mM); Clear solution

*All of the co-solvents are available by MedChemExpress (MCE).

Purity & Documentation

Purity: ≥99.0%

Select Batch:

Data Sheet (273 KB) SDS (392 KB)

COA (248 KB)

Handling Instructions (2659 KB)

References

[1]. Gross, G., G. Hanft, and N. Kolassa, Urapidil and some analogues with hypotensive properties show high affinities for 5-hydroxytryptamine (5-HT) binding sites of the 5-HT1A subtype and for alpha 1-adrenoceptor binding sites. Naunyn Schmiedebergs Arch Pharmacol, 1987. 336(6): p. 597-601. [Content Brief]

[2]. Buch, J., Urapidil, a dual-acting antihypertensive agent: Current usage considerations. Adv Ther, 2010. 27(7): p. 426-43. [Content Brief]

[3]. Vanhaesebrouck S, et al. Neonatal transient respiratory depression after maternal urapidil infusion for hypertension. Eur J Pediatr. 2009 Feb;168(2):221-3. [Content Brief]